A PHASE II STUDY OF LOW-DOSE INTERLEUKIN-2 BY SUBCUTANEOUS INJECTION IN COMBINATION WITH ANTIRETROVIRAL THERAPY VERSUS ANTIRETROVIRAL THERAPY ALONE IN PATIENTS WITH HIV-1 INFECTION AND AT LEAST 3 MONTHS STABLE ANTIRETROVIRAL THERAPY: